- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05348343
Activated PRP for Treatment of Androgenetic Alopecia
A Pilot Clinical 'Proof of Concept' Study of Activated Platelet-rich Plasma (PRP) in Subjects With Androgenetic Alopecia (AGA)
A clinical trial to assess the effects and safety of PRP activated with pulsed electrical fields (PEFA-PRP) compared with unactivated PRP when used to treat AGA.
The design of this small-scale, phase 1b/2a clinical trial is to demonstrate that pulsed electric field activation of autologous PRP results in a controlled release of platelet growth factors and other biologically active molecules that will have a benefit effect on the non-cycling hair follicles in the treated scalp compared to non-activated PRP. This single-center, auto-controlled study will compare the clinical benefit of PEFA-PRP versus non-activated PRP treatment of male patients with AGA.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Anticipated)
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Contact
- Name: Kristen Kelley
- Phone Number: 781-744-1375
- Email: kristen.j.kelley@lahey.org
Study Locations
-
-
Massachusetts
-
Burlington, Massachusetts, United States, 01803
- Recruiting
- Lahey Hospital and Medical Center
-
Contact:
- Kristen Kelley
- Phone Number: 781-744-1375
- Email: kristen.j.kelley@lahey.org
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Male between 30 and 60 years of age, inclusive
- A clinical diagnosis of AGA (stage II to V, according to the Hamilton-Norwood Scale)
- Non-smokers in good general health, as determined by the Investigator
- Willing and able to tolerate multiple injections and attend all study visits
- Willing to maintain the same hair style as at the Screening Visit for the duration of the study
- Willing to have blood drawn.
Exclusion Criteria:
- Clinical diagnosis of alopecia areata or other non-AGA forms of alopecia
- Scalp hair loss on the treatment area, due to disease, injury, or medical therapy
- Current significant skin disease (e.g., psoriasis, atopic dermatitis, skin cancer, eczema, sun damage, seborrheic dermatitis) that might interfere with the study conduct or evaluations
- History of surgical correction for hair loss such as transplantation
- Previous exposure to Platelet-rich Plasma (PRP) for alopecia
- Use of any products or devices purported to promote scalp hair growth (e.g., finasteride or minoxidil) within 30 days prior to the Screening Visit
- Use of anti-androgenic therapies (e.g., spironolactone, flutamide, cyproterone acetate, cimetidine) within 30 days prior to the Screening Visit
- No history of burning, flaking, itching, and stinging of the scalp
- History of malignancy (except basal cell and squamous cell skin cancers) or undergoing chemotherapy or radiation treatments
- A known history of autoimmune thyroid disease, any other thyroid disorder or other autoimmune disorders that in the opinion of the investigator may interfere with the study treatment
- Significant tendency to develop keloids or hypertrophic scarring
- A known history of significant physical or mental disease that the Investigator feels may impact the subject's participation
- The use of aspirin or other NSAIDs (Nonsteroidal anti-inflammatory drugs) such as Nurofen, Voltaren, Diclofenac or Naproxen 7 days before beginning each of the treatments during the study
- The use of Vitamin E supplements (other than in multivitamins) 14 days before beginning each of the treatments during the study
- Current anticoagulant therapy (heparins; factor Xa inhibitors; direct agents such dabigatran, rivaroxaban, apixaban, edoxaban and betrixaban; warfarin/coumarins
- Hereditary or acquired hematological/coagulation disorders such as: platelet dysfunction syndrome, critical thrombocytopenia, hypofibrinogenemia, impaired coagulation, drepanocytosis (sickle cell anemia)
- Utilization of low-level lasers to scalp within 90 days prior to the Screening Visit
- Platelet count of less than 150,000 platelets/µL as measured by automated complete blood cell count and differential at or around the time of treatment (within 3 days of injection)
- Treatment with another investigational drug or other intervention within the previous 180 days
- Current smoker or tobacco use within the previous 2 years
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
OTHER: Autocontrolled Arm
The subject will be treated with both the experimental treatment and the active comparator.
|
PRP created using a commercially available system will be used for treatment.
PEFA-PRP will be created by subjecting PRP to a pulsed electrical field in a specially designed instrument developed by sponsor.
Two 9 cm2 contralateral regions of interest (ROI) on the scalp will be treated with approximately 6mL of either PRP or PEFA-PRP by subcutaneous injection.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in hair density and hair regrowth
Time Frame: Month 6 and Month 8
|
The change in hair density (hair count and thickness) measured in the region of interest (ROI) at six months and eight months using automated image analysis with Trichovision/Fotofinder imaging software. The change will be compared to the following:
|
Month 6 and Month 8
|
Measurement of hair regrowth
Time Frame: Month 6 and Month 8
|
The amount of hair regrowth measured in the region of interest (ROI) at six months and eight months using automated image analysis with Trichovision/Fotofinder imaging software. The change will be compared to the following:
|
Month 6 and Month 8
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Clinical progression of treatment as determined by principal investigator
Time Frame: Month 6 and Month 8
|
Global photography evaluation by the PI using Norwood Hamilton scale.
|
Month 6 and Month 8
|
Clinical progression of treatment as determined by subject
Time Frame: Month 6 and Month 8
|
Change in reported patient satisfaction outcome surveys.
|
Month 6 and Month 8
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Maryanne M. Senna, MD, Lahey Hospital & Medical Center
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ANTICIPATED)
Study Completion (ANTICIPATED)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- SM-001
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Androgenetic Alopecia
-
University of FloridaWithdrawnFemale Androgenetic AlopeciaUnited States
-
Suzhou Kintor Pharmaceutical Inc,Completed
-
King Edward Medical UniversityCompletedCombination of SVF and PRP for Androgenetic AlopeciaPakistan
-
Second Affiliated Hospital, School of Medicine,...Recruiting
-
Hope Medicine (Nanjing) Co., LtdRecruitingAndrogenetic AlopeciaChina
-
Indonesia UniversityRecruiting
-
Cassiopea SpAICON Clinical Research; Canfield Scientific Inc.; Ergomed PLC; Pharmapace IncRecruitingAlopecia, AndrogeneticGermany, United States, Poland
-
University of ArizonaTransdermal Cap, Inc.Not yet recruitingAndrogenetic Alopecia
-
Gregory L Smith, MD, MPHRecruitingAndrogenetic AlopeciaUnited States
-
Indonesia UniversityCompletedAndrogenetic AlopeciaIndonesia
Clinical Trials on Autologous platelet-rich plasma
-
Rajavithi HospitalRecruitingAutologous Platelet-rich Plasma Supplement | Sperm Cryopreservation | Post-cryopreserved Sperm Quality | Semen AnalysisThailand
-
Genesis Athens ClinicNational and Kapodistrian University of AthensRecruitingMenopause, Premature | Menopausal Syndrome | Premature Ovarian Failure | Ovarian Failure, Premature | Menopause Related ConditionsGreece
-
Assiut UniversityUnknownAutologous Platelet Rich Plasma Effect on Bone Healing
-
Mayo ClinicCompleted
-
Center for Vulvovaginal DisordersCompletedLichen Sclerosus
-
Matthew GettmanCompleted
-
Sixth Affiliated Hospital, Sun Yat-sen UniversityRecruiting
-
University of Colorado, DenverCompletedPlatelet-Rich PlasmaUnited States
-
Genesis Athens ClinicNational and Kapodistrian University of AthensRecruitingInfertility, Female | Perimenopausal Disorder | Menstrual Cycle AbnormalGreece
-
Genesis Athens ClinicNational and Kapodistrian University of AthensRecruitingInfertility, Female | Ovarian Failure | Ovarian Insufficiency | Poor Response to Ovulation Induction | Reproductive Sterility | Ovary; AnomalyGreece